^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
FusionPlex® Dx

Type:
CE Marked
Related tests:

Details

Evidence
FusionPlex® Dx is an RNA-based targeted gene panel for detecting biomarkers implicated in the most prevalent solid tumors, especially non-small cell lung cancer (NSCLC). The panel covers ESMO-recommended targets including MET, NTRK1-3, ALK, ROS1, and RET, in addition to pan-tumor comprehensive genomic profiling, and provides highly actionable and quick therapy guidance. Coverage also includes 41 analytical biomarkers, such as FGFR1-3 and NRG1, plus additional key biomarkers to advance precision oncology by providing broader therapy options and optimal clinical trial enrollment. The panel is validated for use on Illumina® MiSeqDx and Illumina NextSeq 550Dx sequencers. It is powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing product, even without prior knowledge of fusion partners or breakpoints.
Cancer:
Non Small Cell Lung Cancer, Solid Tumor
Gene:
ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), AXL (AXL Receptor Tyrosine Kinase), BRAF (B-raf proto-oncogene), BRD4 (Bromodomain Containing 4), DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1)
See More ...
Method:
Comprehensive Genomic Profiling
Approvals
Date
Cancer
Gene
Drug
By
02/16/22
CE